FDA Approves Genus PIC's Gene-Edited PRRS-Resistant Pigs in Landmark Decision
• The U.S. Food and Drug Administration has granted approval for Genus PIC's gene-edited pigs resistant to Porcine Reproductive and Respiratory Syndrome (PRRS), marking a significant milestone in agricultural biotechnology.
• Despite FDA approval, Genus plans to delay broad U.S. commercialization until key export markets including Mexico, Canada, Japan, and China also grant regulatory clearance to ensure market viability.
• PRRS costs the global pork industry approximately $2 billion annually, with the gene-edited solution potentially reducing antibiotic use by over 200% while improving animal welfare and farm economics.
© Copyright 2025. All Rights Reserved by MedPath